My new Clinical Pipeline column is out in Nature Medicine.
It's on JAK inhibitors for alopecia - and at the black box safety warning the FDA attached to this entire class of drugs.

nature.com/articles/d41591-023

@cyrilpedia nice piece, and also informative. Had missed the black box warning on the whole JAK Stat family! Is the increased cardiovascular risk dose / time dependent, or is it idiosyncratic?

@gpollara I don't think we have enough data on that - the group that generated the warning (in another trial set) was oder and had a range of pre-existing conditions.

@cyrilpedia interesting. You can see how a signal came out in that population. My hunch is that it's time & dose dependent, but that doesn't massively help in autoimmune conditions in which treatment is long, spanning into years potentially.

Thank you.

Follow

@gpollara I agree completely - this is a lifelong treatment. I'm in NY right now and the advertisements for ruxolitinib are everywhere.

@cyrilpedia honestly, speaking from a UK perspective, the idea that (obviously non-generic) drugs are marketed straight to patients utterly bemusing!

Is the idea genuinely that the half-informed patient sees it and then goes to their doctor asking about/for it?!

Sign in to participate in the conversation
Qoto Mastodon

QOTO: Question Others to Teach Ourselves
An inclusive, Academic Freedom, instance
All cultures welcome.
Hate speech and harassment strictly forbidden.